ストックスクリーナーアプリを入手
1.69
3.98%
-0.07
前日終値:
$1.76
開ける：
$1.723243
24時間の取引高:
13,881
Relative Volume:
0.10
時価総額：
$188.77M
収益：
$3.13M
当期純損益:
$-55.77M
株価収益率:
-2.7502
EPS:
-0.6145
ネットキャッシュフロー:
$-61.24M
1週間 パフォーマンス:
-11.52%
1か月 パフォーマンス:
-23.36%
6か月 パフォーマンス:
+34.13%
1年 パフォーマンス:
-8.15%
1日の値動き範囲:
$1.69
$1.73
1週間の範囲:
$1.69
$1.94
52週間の値動き範囲:
$1.17
$2.71
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.69 | 196.59M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
522.86 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.74 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
186.44 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
957.20 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
194.84 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-09-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | 開始されました | BTIG Research | Buy |
| 2021-09-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 開始されました | Goldman | Neutral |
すべてを表示
Innate Pharma Adr (IPHA) 最新ニュース
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Innate Pharma stock maintained at Buy by H.C. Wainwright - Investing.com
Innate Pharma Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip - Investing.com India
Innate Pharma, Grove, and more set to report earnings Thursday - Investing.com
Innate Pharma closes Sobi partnership, receives $75m upfront - Investing.com
Innate Pharma at H.C. Wainwright conference: narrower pipeline, bigger bets By Investing.com - Investing.com India
Innate Pharma S.A. ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - sharewise.com
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
FY2026 EPS Estimates for Innate Pharma Reduced by Analyst - MarketBeat
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com South Africa
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com India
Innate Pharma partners with Sobi on lacutamab development - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer - Investing.com
Innate Pharma (IPHA) Holds Steady at $1.68 as Consolidation Pattern DeepensVWAP Bounce - vinanet.vn
Innate Pharma completes enrollment in IPH4502 phase 1 study - Investing.com
Innate Pharma completes enrollment in IPH4502 phase 1 study By Investing.com - Investing.com South Africa
IPHA Q1 2026 Earnings: Significant EPS Miss on R&D InvestmentsEPS Surprise History - po-news-eg.net
Form 13G Innate Pharma SA For: 22 June By Investing.com - Investing.com South Africa
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
IPHAInnate Pharma ADR Stock Price and Quote - Finviz
AUTL - Finviz
IPHA Technical Analysis | Trend, Signals & Chart Patterns | INNATE PHARMA SA-SPONS ADR (NASDAQ:IPHA) - ChartMill
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 beats earnings expectations - Investing.com
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Innate Pharma Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q1 2026 revenue beats forecasts - Investing.com
Unusual VolumeStock ScreenerNews - Finviz
Innate Pharma reports interim lung cancer trial results By Investing.com - Investing.com South Africa
Innate Pharma reports interim lung cancer trial results - Investing.com
HC Wainwright Decreases Earnings Estimates for Innate Pharma - MarketBeat
Top GainersStock ScreenerSnapshot - Finviz
Innate Pharma (IPHA) outlines oncology pipeline and key risks in Form 20-F - Stock Titan
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest - MarketBeat
Innate Pharma Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q4 2025: Strategic Focus Amid Cost Management - Investing.com
Innate Pharma reports 55% revenue drop, expects cash runway until end of Q3 2026 - Investing.com
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update - marketbeat.com
Innate Pharma stock initiated with buy rating at BTIG on oncology pipeline - Investing.com
NASDAQ New 52-Week Highs And Lows - Moomoo
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - investing.com
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma Adr (IPHA) 財務データ
収益
当期純利益
現金流量
EPS
1.01%
1.44%
大文字化:
|
ボリューム (24 時間):